Skip to main content
. 2017 Jul 17;114(31):8396–8401. doi: 10.1073/pnas.1620068114

Fig. 2.

Fig. 2.

EOPs at the inflamed site participate in the antihyperalgesic effects of sigma-1 antagonists. Mice were evaluated 3 h after i.pl. injection with carrageenan (inflamed) or saline (noninflamed). Animals were treated s.c. with sigma-1 antagonists (BD-1063 and S1RA) or solvent controls and subjected to mechanical (A and B) or thermal stimulation (C and D). Mice were also treated i.pl. with 3-E7 anti-EOP monoclonal antibody, its isotype control, or solvent control in the same paw (ipsi) as carrageenan or saline (A and C) or in the paw contralateral (contra) to carrageenan (B and D). All mice received sensory stimulation in the paw into which carrageenan or its solvent was injected. Bars show means ± SEM from 8 to 10 animals. **P < 0.01, mice without inflammation treated with the solvent of the drugs or antibodies vs. mice with inflammation; ##P < 0.01, mice with inflammation treated with sigma-1 antagonists vs. mice with inflammation treated with solvent control; ††P < 0.01, mice with inflammation treated with a sigma-1 antagonist alone vs. mice with inflammation treated with 3-E7 antibody in the inflamed paw; one-way ANOVA followed by Bonferroni test.